ArticleJournal of hepatocellular carcinoma2026
Development and Validation of the TCAP Nomogram for Predicting Hepatotoxicity Risk in Hepatocellular Carcinoma Patients Receiving TACE Combined with Systemic Therapy.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The combination of transarterial chemoembolization (TACE) with molecular targeted therapy and/or immune checkpoint inhibitors (ICIs) has emerged as a cornerstone treatment for intermediate-to-advanced hepatocellular carcinoma (HCC). However, the risk of hepatotoxicity associated with these multimodal regimens remains inadequately characterized. This study aimed to evaluate the incidence, severity, and independent predictors of hepatotoxicity, and to develop a clinically practical prediction model. Materials and Methods: This retrospective study analyzed data from 200 HCC patients treated at Shandong First Medical University Affiliated Cancer Hospital between October 2021 and July 2024. Patients received either TACE plus tyrosine kinase inhibitors (TKIs) (n=120) or TACE plus TKIs and ICIs (n=80). Hepatotoxicity was graded according to CTCAE v5.0 criteria. Multivariate logistic regression was employed to identify independent risk factors and construct a predictive nomogram. Results: The overall hepatotoxicity incidence was 38.00%, predominantly mild-to-moderate (Grade 1: 63.16%; Grade 2: 23.68%; Grade 3: 13.16%). No Grade 4 events occurred, and no significant difference was observed between treatment groups (P=0.637). Multivariate analysis identified four independent predictors: liver cirrhosis (OR=1.684), ALBI Grade 2/3 (OR=6.436), elevated total bilirubin (OR=1.040), and decreased prothrombin activity (OR=0.968). The resulting TCAP (Total bilirubin, Cirrhosis, ALBI grade, Prothrombin activity) nomogram demonstrated robust discriminatory performance (AUC=0.855) with a sensitivity of 82.00% and specificity of 79.10% at the optimal cut-off value of 0.419. Conclusion: The TCAP nomogram provides a reliable, evidence-based tool for individualized hepatotoxicity risk stratification in HCC patients undergoing TACE-based combination therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.